ABSTRACT
Introduction

Disseminated intravascular coagulation (DIC)
is an acquired pathological syndrome, featured by activation of the coagulation pathway which triggers systemic hypercoagulable states. These hypercoagulable states leads to fibrin deposition that interferes with blood flow to the organs, causing organ failure. At the same time, increased consumption of platelets and coagulation factors result in clinical bleeding. DIC itself is not a disease but it is always a complication of an underlying disease. 1 The pathophysiology basics of DIC is the activation of systemic coagulation system that is triggered by the systemic inflammation process. The cause may be constituted by various conditions such as sepsis, obstetric complication, malignancy, and others. This inflammatory process leads to increased procoagulant in hemostatic system. When the body cannot compensate the balance between pro-coagulant and anti-coagulant, it leads to DIC. Based on its distinct features, DIC is classified into Bleeding type, Organ failure type, Massive bleeding type, and Nonsymptomatic type. 1 Comprehensive evaluation is needed in diagnosing DIC, as it has dynamic situation and multifactorial causes. The evaluation must be done comprehensively, between clinical symptoms and laboratory results. Some of the laboratory results that can be considered are platelet counts, FDPs, fibrinogen, and PTaPTT. The diagnosis then can be calculated through ISTH criteria. The focus of DIC management is to treat the underlying disease. In some cases, administration of supportive treatment can be considered, such as blood transfusions, anticoagulation, anticoagulant factor concentrates and anti-fibrinolytic.
-----------------------------------------------------------------------------
The basis of the DIC is the activation of the systemic coagulation cascade that is triggered by systemic inflammation process. In fact, many clinical conditions can lead to activation of systemic coagulation 3 . Table 1 summarizes some of the clinical conditions. 4, 6 Normally, thrombin production is strictly regulated by the natural anticoagulant mechanism (AT-III and Protein C), as well as fibrinolytic mechanism that improve the vascular patency after the formation of hemostatic plug. TFPI decreases coagulation through bind complex into TF/Factor VIIa/Factor Xa. Haemostatis system is vulnerable to disturbance. When the function of endothelial cells is disrupted and the body is unable to compensate the elevated procoagulant, regulation of haemostatis system will be disrupted, causing a DIC The pathogenesis of DIC ( Figure 1 ) is a complex process and centered on elevated intrinsic thrombin production. It is influenced by increased expression of TF, suboptimal functioning of the natural coagulation system, fibrinolysis and increased upregulated phospholipids 5 Disturbance in the endothelium causes the exposure of smooth muscle cells and fibroblast, which will lead to increase TF activity. This can occur in obstetric complication (placental abruption) or severe trauma.
TF is a trans membrane protein co-factors that are constitutively expressed by certain cells, such as fibroblasts. TF will then bind with factor VII to become complex TF/factor VII-a, which then initiate the activation of factor IX and X. TF can also induces activation of ROS that will disrupt the endothelial function. Activities of TF are high in the brain, lungs, and the placenta. Its activation is induced by endothelial cell and monocytes, as a response to cytokines, interleukin-1 (IL-1) and tumor necrosis factor (TNF), or endotoxin 6 Cytokines, along with its pro-inflammatory function, attracts the neutrophils and monocytes. Neutrophils produce neutrophil elastase, which has several effects: 1) inhibit the thrombomodulin activities, which will decrease the activation of activated protein C, 2) decrease the fibrinolytic protease activity, and 3) cause a direct injury to the endothelial cells. The cytokines can also activate PAI-1 that will disrupt the fibrinolytic process. A combination of these complex processes will result in increased formation of thrombin through activation of P-selectin and PAF 1 Same with every physiological hemostatic process, coagulation cascade will induce the activation of t-PA, triggering a fibrinolysis process which will produce FDPs. These FDPs have a negative feedback to the platelet activation, making the body into a bleeding state. Moreover, increased consumption of platelets and coagulation factors are contributed to the bleeding symptoms 6 
Types
In accordance with its pathogenesis, DIC can occur due to the result of the two vectors, namely hyper-coagulation and hyperfibrinolytic state 4 ( Figure 2 ) Figure 2 . Bleeding, Organ failure, Massive Bleeding, and Non-symptomatic type of DIC. 4 In the state of hyper-fibrinolytic dominant, bleeding is the main symptom; this type is known as a bleeding type (BL) or hyperfibrinolysis predominance type of DIC. This type is often found in patients with leukemia such as APL, complications of pregnancy, or aortic aneurysm. In other circumstances, when a hypercoagulable state vector is more dominant, organ failure is the main symptom; type known as organ failure (OF) or hypercoagulation predomination hypo-fibrinolysis type or type of DIC. This type is often found in patients with severe infection or sepsis 6 Increased cytokines and lipopolysaccharide resulted in increased activation of PAI-1 in intravascular, which will lead to hypofibrinolysis 4, 6 If both vectors occur simultaneously, massive hemorrhage can occur, and may lead to death if transfusion is not given immediately; this type is referred to as massive bleeding (MB) or consumptive type of DIC.
This type is observed in patients with massive bleeding after surgical procedures or obstetric complications. Finally, when the both vectors are weak, there will be no clinical symptoms, although some abnormalities appear in laboratory results; This type is referred to as non-symptomatic DIC (NS) or pre-DIC. This classification is done to facilitate the diagnosis and management of the four types. It is important to remember that the state of DIC may shift and change. Observation needs to be done daily 5, 6 We should also know that DIC with solid tumors cannot be classified into these four types, hence it should be observed seperately 6 
Clinical Symptoms
Two distinct features that can happen simultaneously makes clinical symptoms of DIC varies, based on its underlying diseases. If the clinical state is more likely to hypercoagulation or hypo-fibrinolytic state, then the ischemic symptoms (OF) will be dominant.
Conversely, if the clinical state is more likely to hypo-coagulation or hypo-fibrinolytic state, then the bleeding symptoms (BL) will be dominant [4] [5] [6] [7] (Table 2) 
Diagnosis
The syndrome of DIC is a multifactorial and always a complication of an underlying disease. Thus, it is important to assess the whole clinical picture, evaluation between the clinical condition of the patient and the laboratory results. It is also important to remember that the state of DIC is an extremely dynamic situation, hence a daily evaluation and observation should be done. The diagnosis cannot be made with one laboratory test as each of them has low specificity to DIC. Some of the laboratory results that can be considered are platelet counts, FDPs, fibrinogen, and PT-aPTT 5 
Platelet Count
Moderate-to-severe thrombocytopenia (platelet count <100 x 10 9 /l) is observed in most DIC patients, while severe thrombocytopenia (platelet count <50 x 10 9 /l) is seen in 10-15% of DIC. These low platelet counts result is associated with increased risk of bleeding complications.
Patients with severe thrombocytopenia have a five times higher risk of bleeding than patients with a normal platelet count 9 Keep in mind that a stable platelet count is a sign of no thrombin production. Low platelet count is sensitive markers for DIC, but not specific. Several conditions can lead to thrombocytopenia without DIC, such as acute leukemia, or sepsis 5, 9 
FDPs and D-dimer
Increased fibrinolysis activity caused by elevated thrombin production, will lead to an increase in FDPs. However, it is necessary to remember that many conditions can cause an increase in FDPs and D-dimer, which are trauma, surgical history, venous thromboembolism. Because these fragments are metabolized in the liver and excreted by kidneys, disturbance to both organs will lead to increased FDPs and D-dimer levels 5, 9 
Fibrinogen
Fibrinogen acts as an acute-phase reactant. Apart from the consumption of fibrin, plasma levels could remain at normal levels for a long time. Low fibrinogen levels only has a sensitivity 28% for diagnosing DIC. Hypofibrinogenemia is only detected in the case of heavy DIC. Its level may be normal in 57% of the DIC patient 9
PT and aPTT
Prolonged PT and aPTT is seen only in 50-60% of patients with DIC. It can also occurs in liver function disorders, vitamin K deficiency, and bleeding. Increased circulation of active complex coagulation factors can cause a shorten PT and aPTT 5, 9 To facilitate the diagnosis of DIC, the Sub-Committee of the International Society on Thrombosis and hemostasis (ISTH) for DIC, together with the Scientific and Standardization Committee (SSC) to recommend the use of DIC scoring system for overt or acute. Overt DIC is a condition in which the endothelial cells and its components lose the ability compensate, and is unable to restore hemostatic. Criteria ISTH introduces a 5-step diagnostic algorithm (Table 3) to calculate the scoring KID. The diagnosis of overt DIC is made when a cumulative score of 5 or more, in prolonged PT, thrombocytopenia, a decrease in the numbers of fibrinogen, and increased FDP or D-dimer 9 Non overt DIC is a state where there is a disturbance to the endothelial, but the body is still able to compensate and so the clinical manifestation is not seen. The diagnosis of nonovert DIC use a different set diagnostic algorithm scoring system (Table 4) 10 Figure 4 . Scoring system for non-overt DIC.
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Management
The core treatment of DIC focuses on treating the underlying diseases, such as administrating antibiotics to patients with infections, anticancer drugs or surgical treatment in patients with malignancy 9 DIC can improve spontaneously when the underlying disease is treated, although in some cases additional supportive treatment is needed to correct abnormalities in the coagulation system 4 Based on its type, treatment for BL, OF and NS type of DIC focus on treating the underlying diseases, whereas MB type of DIC is started with blood transfusion 4 
Blood Transfusion
Patient with low platelet and coagulation factors increase the risk of bleeding. However, transfusion therapy should not be based on laboratory results alone. Evaluation on the whole picture is a must, for example, in patients with active bleeding, or patient who will undergo invasive procedures, or in high risk of bleeding complication 5 General administration of platelet transfusion in patients with bleeding presentation starts at ≤ 50 x 10 9 /L, whereas patients with no bleeding presentation starts at 10 -20 x 10 9 /L. Platelet transfusion is generally given to BL or MB type of DIC 4 Initial dose given is 0.1-0.2 units/kg 9 Fresh Frozen Plasma (FFP) administration can be given to patients with several indications, such as prolonged PT-aPTT> 1.5 times normal, or fibrinogen <1.5 g / dL, or in patients KID with active bleeding and prolonged PT-aPTT 4 Initial doses recommended is 15 ml/kg, although there is some evidence suggest that 30 ml/kg dose given may produce more satisfying results 5 Correction with FFP administration needs to be observed, as it may exacerbate the state of excess fluid.
In this circumstance, consider administration of factor concentrates such as prothrombin complex concentrates instead. However, because there is a massive deficiency of the whole coagulation factors in DIC, giving this factor concentrates can only correct a deficiency of coagulation factors partially 4, 5 In some cases of DIC, hypo-fibrinogenemia (fibrinogen <1 g / dL) may occur. The fibrinogen deficiency can be corrected by using cryoprecipitate transfusion. 3 g dose of plasma fibrinogen is expected to increase as much as 1 g/L. PRC administration in patients with active and/or massive bleeding can also be done, with a target Hb>8 5 The response of transfusion therapy should be observed and evaluated periodically 4, 5, 9 Anticoagulant Administration of anticoagulant to decrease the hyper-coagulation is still on debate 9 However, in cases of DIC where hypercoagulable state predominates (severe purpura fulminant associated with acral ischemia or vascular skin infarction, arterial or venous thromboembolism), therapeutic doses of heparin should be considered. The therapeutic dose is 15.000-20.000 U/12 day or 8000-10.000 U/8 hr. If the patient is in high risk bleeding, continuous infusion 10 U/kg/h of Unfractionated Heparin should be considered. Cases where the DIC patients are critically ill with no bleeding presentation, prophylaxis doses of heparin or low molecular weight heparin for venous thromboembolism is recommended 5, 9 Anticoagulant Factor Concentrates Anti-thrombin (AT) concentrate administration has shown an improvement in the results of laboratory tests, but does not have a significant reduction in mortality. Decreased concentration of protein C in the DIC state is one of the reasons of Activated Protein C (APC) administration. A large randomized controlled trial showed that APC administration can effectively reduce mortality and organ failure in severe sepsis with DIC. Mortality percentage by administration of APC in a DIC patients group is 24%, while the placebo administration is 30%. Though it is reported that bleeding is more common in the group of patients with APC administration 5 Initial dose can be administered by continuous infusion, 24 g/kg/day for 4 days. This therapy is not recommended in patients with a high risk of bleeding and/or with platelet count ≤ 30 x 109/l 5, 9 Anti-fibrinolytic Anti-fibrinolytic administration is not recommended in patients with bleeding presentation. In DIC where the state of dominant hyper-fibrinolysis (as in AML-M3 or prostate cancer) is exceptional. The recommendation dose for anti-fibrinolytic administration is tranexamic acid 1 g/8hrs. KID exception for cases where the state hyperfibrinolysis more dominant (as in AML-M3 or prostate cancer), recommended the granting anti-fibrinolytic tranexamic acid dose of 1 g / 8 hours 5 .
